Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
E-pub ahead of print

Calcitonin gene related peptide in migraine: current therapeutics, future implications and potential off-target effects

Research output: Contribution to journalReviewpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Ray, Jason Charles ; Kapoor, Mahima ; Stark, Richard J ; Wang, Shuu-Jiun ; Bendtsen, Lars ; Matharu, Manjit ; Hutton, Elspeth Jane. / Calcitonin gene related peptide in migraine : current therapeutics, future implications and potential off-target effects. In: Journal of neurology, neurosurgery, and psychiatry. 2021.

Bibtex

@article{7162d78ab5a34ad5985cb2f86a3646fc,
title = "Calcitonin gene related peptide in migraine: current therapeutics, future implications and potential off-target effects",
abstract = "Migraine is the second largest cause of years lost to disability globally among all diseases, with a worldwide prevalence over 1 billion. Despite the global burden of migraine, few classes of therapeutics have been specifically developed to combat migraine. After 30 years of translational research, calcitonin gene-related peptide (CGRP) inhibitors have emerged as a promising new tool in the prevention of migraine. Like all new therapeutics; however, we have limited real-world experience and CGRP has several known systemic actions that warrant consideration. This article provides a narrative review of the evidence for CGRP antagonists and summarises the known and potential side effects that should be considered.",
keywords = "drug trials, headache, migraine",
author = "Ray, {Jason Charles} and Mahima Kapoor and Stark, {Richard J} and Shuu-Jiun Wang and Lars Bendtsen and Manjit Matharu and Hutton, {Elspeth Jane}",
note = "{\textcopyright} Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.",
year = "2021",
doi = "10.1136/jnnp-2020-324674",
language = "English",
journal = "Journal of Neurology, Neurosurgery and Psychiatry",
issn = "0022-3050",
publisher = "B M J Group",

}

RIS

TY - JOUR

T1 - Calcitonin gene related peptide in migraine

T2 - current therapeutics, future implications and potential off-target effects

AU - Ray, Jason Charles

AU - Kapoor, Mahima

AU - Stark, Richard J

AU - Wang, Shuu-Jiun

AU - Bendtsen, Lars

AU - Matharu, Manjit

AU - Hutton, Elspeth Jane

N1 - © Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

PY - 2021

Y1 - 2021

N2 - Migraine is the second largest cause of years lost to disability globally among all diseases, with a worldwide prevalence over 1 billion. Despite the global burden of migraine, few classes of therapeutics have been specifically developed to combat migraine. After 30 years of translational research, calcitonin gene-related peptide (CGRP) inhibitors have emerged as a promising new tool in the prevention of migraine. Like all new therapeutics; however, we have limited real-world experience and CGRP has several known systemic actions that warrant consideration. This article provides a narrative review of the evidence for CGRP antagonists and summarises the known and potential side effects that should be considered.

AB - Migraine is the second largest cause of years lost to disability globally among all diseases, with a worldwide prevalence over 1 billion. Despite the global burden of migraine, few classes of therapeutics have been specifically developed to combat migraine. After 30 years of translational research, calcitonin gene-related peptide (CGRP) inhibitors have emerged as a promising new tool in the prevention of migraine. Like all new therapeutics; however, we have limited real-world experience and CGRP has several known systemic actions that warrant consideration. This article provides a narrative review of the evidence for CGRP antagonists and summarises the known and potential side effects that should be considered.

KW - drug trials

KW - headache

KW - migraine

U2 - 10.1136/jnnp-2020-324674

DO - 10.1136/jnnp-2020-324674

M3 - Review

C2 - 33495299

JO - Journal of Neurology, Neurosurgery and Psychiatry

JF - Journal of Neurology, Neurosurgery and Psychiatry

SN - 0022-3050

ER -

ID: 62004232